keyword
MENU ▼
Read by QxMD icon Read
search

anthracycline induced cardiomyopathy

keyword
https://www.readbyqxmd.com/read/28428026/dietary-cyanidin-3-glucoside-from-purple-corn-ameliorates-doxorubicin-induced-cardiotoxicity-in-mice
#1
K Petroni, M Trinei, M Fornari, V Calvenzani, A Marinelli, L A Micheli, R Pilu, A Matros, H-P Mock, C Tonelli, M Giorgio
BACKGROUND AND AIMS: Anthracyclines are effective anticancer drugs that have improved prognosis of hundred thousand cancer patients worldwide and are currently the most common chemotherapeutic agents used for the treatment of blood, breast, ovarian and lung cancers. However, their use is limited because of a cumulative dose-dependent and irreversible cardiotoxicity that can cause progressive cardiomyopathy and congestive heart failure. Aim of the present study was to determine the cardioprotective activity of a dietary source of cyanidin 3-glucoside (C3G), such as purple corn, against doxorubicin (DOX)-induced cardiotoxicity in mice...
February 21, 2017: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/28361826/preventive-role-of-carvedilol-in-adriamycin-induced-cardiomyopathy
#2
Rajesh Jhorawat, Savita Kumari, Subhash C Varma, Manoj K Rohit, Nidhi Narula, Vikas Suri, Pankaj Malhotra, Sanjay Jain
BACKGROUND & OBJECTIVES: Adriamycin though considered as an effective anticancer drug, leads to irreversible cardiomyopathy (CMP) and congestive heart failure (CHF). The aim of this study was to determine the protective effect of carvedilol in adriamycin (ADR)-induced cardiomyopathy (CMP) in cancer patients. METHODS: Patients with lymphoreticular malignancy in whom ADR therapy was planned were randomized into two groups: carvedilol and control. Twenty seven patients each were enrolled in carvedilol and control groups...
November 2016: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/28315399/truncating-titin-ttn-variants-in-chemotherapy-induced-cardiomyopathy
#3
M Linschoten, A J Teske, A F Baas, A Vink, D Dooijes, H F Baars, F W Asselbergs
Chemotherapy-induced cardiomyopathy (CCMP) is a complication of chemotherapy treatment occurring in 9% of patients treated with anthracyclines. Currently, risk stratification is based on clinical risk factors that do not adequately explain the variable individual susceptibility. This points towards the presence of other determinants. In this case series, we describe two women with breast cancer that developed severe heart failure within months after chemotherapy. Genetic screening revealed truncating frameshift mutations in TTN, encoding the myofilament titin, in both women...
March 14, 2017: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/28290834/-the-time-course-of-formation-of-systolic-dysfunction-of-the-heart-in-doxorubicin-cardiomyopathy
#4
V L Lakomkin, A A Abramov, V V Gramovich, O N Vyborov, E V Lukoshkova, V V Ermishkin, V I Kapelko
The anthracycline-induced cardiomyopathy is a frequent and menacing complication of antitumor therapy leading to chronic heart failure. A study of the formation of heart failure can reveal early signs of the development of systolic dysfunction of the heart. In this work in rats we studied cardiac function at different duration of doxorubicin treatment, the most effective anthracycline antibiotic. Cumulative doses of doxorubicin were 8-20 mg/kg, and the term of study lasted from 6 to 20 weeks. The echocardiography and catheterization of the left ventricle (LV) have been use...
January 2017: Kardiologiia
https://www.readbyqxmd.com/read/28285949/considerations-in-cardio-oncology-multiple-mobile-left-sided-cardiac-thrombi-in-chemotherapy-induced-cardiomyopathy
#5
Toshinori Minamishima, Kenichi Matsushita, Hiromu Morikubo, Aoi Isaka, Noriko Matsushita, Hidehito Endo, Hiroshi Kubota, Konomi Sakata, Toru Satoh, Hideaki Yoshino
With advances in cancer chemotherapy, the importance of the new clinical discipline of cardio-oncology, which is concerned with the cardiac effects of chemotherapy, is increasing. Herein we describe the case of a 48-year-old woman with a history of breast cancer who presented with symptoms of heart failure due to chemotherapy-induced cardiomyopathy. Treatment for the patient's breast cancer had included surgery and chemotherapy with anthracyclines and trastuzumab. Echocardiography revealed multiple mobile thrombi in the left ventricle and atrium...
March 10, 2017: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/28265217/titanium-plug-closure-after-heartware-ventricular-assist-device-explantation-in-a-15-year-old-girl-first-u-s-experience
#6
Diego A Lara, Aamir Jeewa, Barbara A Elias, Elizabeth O McCullum, Susan W Denfield, William J Dreyer, Iki Adachi
We describe the case of a teenage girl with anthracycline-induced cardiomyopathy who received a HeartWare ventricular assist device and underwent successful device explantation after cardiac recovery. During device support, the patient's cardiac function returned to normal. Twelve months after implantation, we explanted the device via repeat median sternotomy. To close the hole in the left ventricular apex and preserve the sewing ring in case future device support is needed, we used a German-manufactured titanium plug, developed specifically for this purpose...
February 2017: Texas Heart Institute Journal
https://www.readbyqxmd.com/read/28261787/signalling-mechanisms-underlying-doxorubicin-and-nox2-nadph-oxidase-induced-cardiomyopathy-involvement-of-mitofusin-2
#7
Declan McLaughlin, Youyou Zhao, Karla M O'Neill, Kevin S Edgar, Philip D Dunne, Anna M Kearney, David J Grieve, Barbara J McDermott
BACKGROUND AND PURPOSE: The anthracycline doxorubicin (DOX), although successful as a first-line cancer treatment, induces cardiotoxicity linked with increased production of myocardial reactive oxygen species (ROS), with Nox2 NADPH oxidase-derived superoxide reported to play a key role. The aim of this study was to identify novel mechanisms underlying development of cardiac remodelling/dysfunction further to DOX-stimulated Nox2 activation. EXPERIMENTAL APPROACH: Nox2(-/-) and wild-type (WT) littermate mice were administered DOX (12mg/kg over 3 weeks) prior to study at 4 weeks...
March 6, 2017: British Journal of Pharmacology
https://www.readbyqxmd.com/read/28256509/customized-laboratory-tlr4-and-tlr2-detection-method-from-peripheral-human-blood-for-early-detection-of-doxorubicin-induced-cardiotoxicity
#8
A L Pop-Moldovan, N-M Trofenciuc, D A Dărăbanţiu, C Precup, H Branea, R Christodorescu, M Puşchiţă
Cancer treatments can have significant cardiovascular adverse effects that can cause cardiomyopathy and heart failure with reduced survival benefit and considerable decrease in the use of antineoplastic therapy. The purpose of this study is to assess the role of TLR2 and TLR4 gene expression as an early marker for the risk of doxorubicin-induced cardiomyopathy in correlation with early diastolic dysfunction in patients treated with doxorubicin. Our study included 25 consecutive patients who received treatment with doxorubicin for hematological malignancies (leukemia, lymphomas or multiple myeloma), aged 18-65 years, with a survival probability>6 months and with left ventricular ejection fraction>50%...
March 3, 2017: Cancer Gene Therapy
https://www.readbyqxmd.com/read/28251781/-123-i-mibg-imaging-for-detection-of-anthracycline-induced-cardiomyopathy
#9
REVIEW
Adam H Laursen, Jens Jakob Thune, Martin Hutchings, Philip Hasbak, Andreas Kjaer, Marie B Elming, Rasmus S Ripa
Due to improvements in early detection and treatment of malignant disease, the population of cancer survivors is constantly expanding. Cancer survivors are faced with chemotherapy-related long-term side effects, including irreversible cardiac injury with risk of heart failure (HF). Numerous antineoplastic regimens are associated with risk of cardiac side effects, but anthracyclines in particular carry a severe risk of cardiotoxicity. Currently, serial echocardiographic evaluation of resting left ventricular ejection fraction (LVEF) is the gold standard for monitoring anthracycline-induced cardiac side effects from chemotherapy...
March 2, 2017: Clinical Physiology and Functional Imaging
https://www.readbyqxmd.com/read/28066861/the-incidence-of-cardiomyopathy-in-brca1-and-brca2-mutation-carriers-after-anthracycline-based-adjuvant-chemotherapy
#10
Edward J Pearson, Anju Nair, Yahya Daoud, Joanne L Blum
PURPOSE: Breast cancer remains the fourth-leading cause of death in the United States. Nearly 10% of breast cancers are hereditary, with deleterious mutations in BRCA1 and BRCA2 genes being the leading cause. Anthracycline chemotherapy, used commonly for breast cancer, carries cardiotoxicity risk. Recent studies demonstrated anthracycline-induced cardiac failure in homozygous BRCA2-deficient mice and increased rates of heart failure in homozygous BRCA1-deficient mice following ischemic insult...
February 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27965861/exercise-to-prevent-anthrcycline-based-cardio-toxicity-exact-in-individuals-with-breast-or-hematological-cancers-a-feasibility-study-protocol
#11
Melanie R Keats, Scott A Grandy, Nicholas Giacomantonio, David MacDonald, Miroslaw Rajda, Tallal Younis
BACKGROUND: Anthracyclines (AC), widely used and effective anticancer agents, are known to induce both acute and chronic declines in cardiovascular health, ranging in severity from asymptomatic, subclinical dysfunction to substantial cardiomyopathy leading to congestive heart failure and death. There is substantial evidence that physical activity, higher levels of cardiorespiratory fitness, and exercise therapy can help prevent cardiovascular disease. Moreover, animal studies have shown that exercise performed concomitantly with AC treatment may attenuate early cardiac damage that results from AC exposure...
2016: Pilot and Feasibility Studies
https://www.readbyqxmd.com/read/27931027/anthracycline-induced-cardiotoxicity-in-young-cancer-patients-the-role-of-carnitine
#12
Saro H Armenian
While the increased rates of survival in childhood cancers have increased progressively in recent decades, many childhood cancer survivors will have at least one chronic health condition within 40 years of age. In this regard, cardiovascular complications have emerged as a leading cause of long-term morbidity and mortality in long-term survivors of childhood cancer, likely due to exposure to anthracycline chemotherapy, and outcomes in patients with anthracycline-related cardiomyopathy remain poor. Some progress has been made in understanding the mechanisms at the basis of anthracycline-related cardiomyopathy, which appear to involve generation of reactive oxygen species, leading to mitochondrial dysfunction, followed by myocyte apoptosis and maladaptive left ventricular remodeling...
2016: Annals of Nutrition & Metabolism
https://www.readbyqxmd.com/read/27926539/chemotherapy-related-cardiac-dysfunction-grey-area-in-type-i-and-type-ii-classification
#13
Rohit Moudgil, Haissam Haddad
PURPOSE OF REVIEW: The main aim of this review is to address and challenge an old nomenclature of reversible versus irreversible chemotherapy-induced cardiomyopathy. RECENT FINDINGS: Chemotherapy-related cardiac dysfunction (CRCD) has been often characterized as type I or type II. Type I CRCD (e.g., anthracycline) represents a group of chemotherapeutic agents that has often been correlated with irreversible cardiac dysfunction. Conversely, type II CRCD (e.g., trastuzumab) represents a group of anticancer agents that has been considered as reversible...
March 2017: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/27861187/genetic-testing-in-cardiomyopathies-an-update-on-indications-and-benefits
#14
Natasha Aleksova, Julie Rutberg, Martin Green, Haissam Haddad
PURPOSE OF REVIEW: As rapid genetic testing has become increasingly accessible in a timely fashion, more genetic mutations are identified in inherited conditions such as cardiomyopathies. Understanding when to consider genetic testing is an important part of the management of patients whose presentations vary from decompensated heart failure to sudden cardiac death. RECENT FINDINGS: We describe the benefits of genetic testing for risk stratification of family members, prognostication of probands, and identification of novel disease-causing mutations and examine the possible role of genetic predisposition in seemingly acquired cardiomyopathies such as peripartum and anthracycline-induced cardiomyopathy...
March 2017: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/27858859/risk-factors-of-trastuzumab-induced-cardiotoxicity-in-breast-cancer-a-meta-analysis
#15
Zeeshan Jawa, Ruth M Perez, Lydia Garlie, Maharaj Singh, Rubina Qamar, Bijoy K Khandheria, Arshad Jahangir, Yang Shi
BACKGROUND: Trastuzumab targets the human epidermal growth factor receptor 2 oncogene and in combination with first-line therapy results in significantly improved survival outcomes and has thus become standard of care in both adjuvant and metastatic settings. While it is estimated that 1% to 4% of patients treated with trastuzumab will develop heart failure and ∼10% will experience a reduction in left ventricular ejection fraction (LVEF), the patient risk factors associated with trastuzumab-induced cardiotoxicity (TIC) are unclear...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27852680/successful-recovery-and-allogeneic-stem-cell-transplant-following-chemotherapy-induced-severe-cardiomyopathy-literature-review-of-management-and-prognostic-factors
#16
REVIEW
Muhammad Asim Shahzad, Rizwan Ishtiaq, Umar Zahid, Faiz Anwer
Chemotherapy-induced cardiomyopathy is one of the major possible hazards that can result from potential cardiotoxic agents while treating cancer. Prognostic risk factors include the rate of drug administration, history of hypertension, female gender, extremes of age, previous history of mediastinal irradiation, cumulative dose and pre-existing heart disease. Close monitoring of the patients, timely diagnosis, use of well-known biomarkers including cardiac troponins, NT-ProBNP and imaging studies like 2D Echo or cardiac MRI are essential...
November 16, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27799559/vegf-b-gene-therapy-inhibits-doxorubicin-induced-cardiotoxicity-by-endothelial-protection
#17
Markus Räsänen, Joni Degerman, Tuuli A Nissinen, Ilkka Miinalainen, Risto Kerkelä, Antti Siltanen, Janne T Backman, Eero Mervaala, Juha J Hulmi, Riikka Kivelä, Kari Alitalo
Congestive heart failure is one of the leading causes of disability in long-term survivors of cancer. The anthracycline antibiotic doxorubicin (DOX) is used to treat a variety of cancers, but its utility is limited by its cumulative cardiotoxicity. As advances in cancer treatment have decreased cancer mortality, DOX-induced cardiomyopathy has become an increasing problem. However, the current means to alleviate the cardiotoxicity of DOX are limited. We considered that vascular endothelial growth factor-B (VEGF-B), which promotes coronary arteriogenesis, physiological cardiac hypertrophy, and ischemia resistance, could be an interesting candidate for prevention of DOX-induced cardiotoxicity and congestive heart failure...
November 15, 2016: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/27755245/novel-insights-in-pathophysiology-of-antiblastic-drugs-induced-cardiotoxicity-and-cardioprotection
#18
REVIEW
Martino Deidda, Rosalinda Madonna, Ruggiero Mango, Pasquale Pagliaro, Pier P Bassareo, Lucia Cugusi, Silvio Romano, Maria Penco, Francesco Romeo, Giuseppe Mercuro
Despite advances in supportive and protective therapy for myocardial function, heart failure caused by various clinical conditions, including cardiomyopathy due to antineoplastic therapy, remains a major cause of morbidity and mortality. Because of the limitations associated with current therapies, investigators have been searching for alternative treatments that can effectively repair the damaged heart and permanently restore its function. Damage to the heart can result from both traditional chemotherapeutic agents, such as anthracyclines, and new targeted therapies, such as trastuzumab...
May 2016: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/27721532/benefits-of-antihypertensive-medications-for-anthracycline-and-trastuzumab-induced-cardiotoxicity-in-patients-with-breast-cancer-insights-from-recent-clinical-trials
#19
Katarzyna Rygiel
Advances in oncologic therapies have allowed many patients with breast cancer to achieve better outcomes and longer survival. However, this progress has been tempered by cardiotoxicity, associated with anticancer therapies, ranging from subclinical abnormalities to irreversible life-threatening complications, such as congestive heart failure or cardiomyopathy. In particular, exposure to chemotherapy (CHT), including anthracyclines and trastuzumab, can lead to cardiac dysfunction with short- or long-term consequences, among patients with breast cancer...
September 2016: Indian Journal of Pharmacology
https://www.readbyqxmd.com/read/27690233/utility-of-dexrazoxane-for-the-attenuation-of-epirubicin-induced-genetic-alterations-in-mouse-germ-cells
#20
Sabry M Attia, Sheikh F Ahmad, Mushtaq A Ansaria, Ahmed Nadeem, Othman A Al-Shabanah, Mohammed M Al-Harbi, Saleh A Bakheet
Dexrazoxane has been approved to treat anthracycline-induced cardiomyopathy and extravasation. However, the effect of dexrazoxane on epirubicin-induced genetic alterations in germ cells has not yet been reported. Thus, the aim of this study was to determine whether dexrazoxane modulates epirubicin-induced genetic damage in the germ cells of male mice. Our results show that dexrazoxane was not genotoxic at the tested doses. Furthermore, it protected mouse germ cells against epirubicin-induced genetic alterations as detected by the reduction in disomic and diploid sperm, spermatogonial chromosomal aberrations, and abnormal sperm heads...
2016: PloS One
keyword
keyword
56258
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"